PD61-05: Oncological outcomes of neoadjuvant degarelix with apalutamide (ARNEO trial) versus standard of care prior to radical prostatectomy for high-risk prostate cancer: a propensity score matched analysis

PD61-05: Oncological outcomes of neoadjuvant degarelix with apalutamide (ARNEO trial) versus standard of care prior to radical prostatectomy for high-risk prostate cancer: a propensity score matched analysis

Monday, May 6, 2024 1:40 PM to 1:50 PM · 10 min. (US/Central)

302A

Delete

Speakers

Alexander Giesen

Alexander Giesen

University of Leuven

Monday, May 6

PD61: Prostate Cancer: Localized: Surgical Therapy IV

Monday, May 6, 2024 1:00 PM to 3:00 PM

Christopher Amling

Reza Ghavamian · Northwell Health

Yaw Nyame · University of Washington Medical Center

Log in

See all the content and easy-to-use features by logging in